Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

379 - Differential effects of corticosteroids and anti-TNF on tumor-specific immune responses: Implications for the management of irAEs

Date

14 Dec 2018

Session

Poster Display session

Presenters

Arianna Draghi

Citation

Annals of Oncology (2018) 29 (suppl_10): x17-x23. 10.1093/annonc/mdy486

Authors

A. Draghi1, T.H. Borch2, H.D. Radic1, C. Chamberlain1, A. Gokuldass1, I. Svane2, M. Donia2

Author affiliations

  • 1 Ccit-center For Cancer Immune Therapy, Herlev and Gentofte Hospital, 2730 - Herlev/DK
  • 2 Ccit-center For Cancer Immune Therapy, Department Of Oncology, Herlev and Gentofte Hospital, 2730 - Herlev/DK
More

Resources

Abstract 379

Background

Up to 60% of patients treated with cancer immunotherapy develop severe or life threatening immune-related adverse events (irAEs). Immunosuppression with high doses of corticosteroids or, in refractory cases, with tumor necrosis factor (TNF) antagonists, are the mainstay of treatment for irAEs. It is currently unknown what is the impact of corticosteroids and anti-TNF on the activity of tumor-specific T cells.

Methods

The influence of clinically relevant doses of dexamethasone (corresponding to an oral dose of 10 to 125 mg oral prednisolone) and infliximab (anti-TNF, corresponding to the steady-state concentration for the infusion dose of 5mg/kg) on the activation and killing capacity of tumor-infiltrating lymphocytes (TILs) or tumor-specific peripheral blood lymphocytes (PBLs) was tested in vitro. The activation of lymphocytes following recognition of autologous tumor cells (percentage of CD8+ T cells staining positive for the activation marker 4-1BB/CD137) was evaluated with flow cytometry at different time points. The tumor-specific killing ability of TILs versus autologous tumor cells was evaluated in the impedance-based xCELLigence system.

Results

Overall, dexamethasone at low or intermediate/high doses impaired the activation (respectively -46% and -62% in n = 8) and tumor-killing ability (respectively -48% and -53% in n = 6) of TILs. However, even high doses of dexamethasone did not abrogate TILs activity. In contrast, a standard clinical dose of infliximab only had a minor effect on the activation and tumor-killing ability of TILs (respectively -20% in n = 8 and -10% in n = 6). Similar results were obtained comparing the activation of tumor-specific CD8+ PBLs. A 72-hour resting after withdrawal of dexamethasone was sufficient to rescue the in vitro activity of TILs, while a short withdrawal did not result in a full rescue.

Conclusions

Clinically-relevant doses of infliximab only influenced to a lesser extent the activity of tumor-specific T cells in vitro, whereas even low doses of corticosteroids markedly impaired their antitumor functions. These data indirectly support steroid-sparing strategies and early initiation of anti-TNF for the treatment of irAEs in immuno-oncology.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

Herlev and Gentofte Hospital.

Funding

These works were supported by a research grant to Inge Marie Svane from The Danish Cancer Society, Knæk Cancer campaign.

Disclosure

T.H. Borch: Honoraria for lectures: Bristol-Myers Squibb; Financial support for attending symposia: Bristol-Myers Squibb, Roche. I-M. Svane: Honoraria for lectures: Novartis, Roche, Merck, Bristol-Myers Squibb; Research grant: Novartis; Financial support for attending symposia: Bristol-Myers Squibb, Merck, Novartis, Pfizer, Roche. M. Donia: Honoraria for lectures: Bristol-Myers Squibb, Merck, AstraZeneca, Genzyme; Financial support for attending symposia: Bristol-Myers Squibb, Merck, Novartis, Pfizer, Roche. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.